Neoadjuvant Cabozantinib for Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma: A Phase 2 Trial

Academic Background Renal Cell Carcinoma (RCC) is one of the cancers with a rapidly rising incidence globally, particularly among young patients and minorities. In the United States, an estimated 81,610 new cases of RCC will be diagnosed in 2024, with approximately 30% progressing to metastatic RCC. For locally advanced RCC, the initial treatment i...

Comparison of Long-Term Survival of Neoadjuvant Therapy Plus Surgery Versus Upfront Surgery and the Role of Adjuvant Therapy for T1b-2N0-1 Esophageal Cancer: A Population Study of the SEER Database and Chinese Cohort

Comparative Study on Treatment Strategies for Esophageal Cancer Academic Background Esophageal cancer is one of the digestive system tumors with high incidence and mortality rates worldwide, particularly in Asia, where the incidence of esophageal squamous cell carcinoma (SCC) is notably prominent. Although significant progress has been made in the ...

Phase Ib Trial of Neoadjuvant Oncolytic Virus OrienX010 and Toripalimab in Resectable Acral Melanoma

Neoadjuvant Oncolytic Virus OrienX010 Combined with PD-1 Inhibitor Toripalimab for Resectable Acral Melanoma: Phase Ib Clinical Trial Background Acral melanoma (AM) is a highly aggressive subtype of melanoma with a high incidence in the Chinese population, accounting for approximately 40% of melanoma cases. Despite advances in melanoma treatment, c...